2-(4-aminobutyl)isoindoline-1,3-dione | 99008-43-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异吲哚及其衍生物
• 英文名称: 2-(4-aminobutyl)isoindoline-1,3-dione
• 英文别名: N¹-phthaloylputrescine；N-[4-(amino)butyl]phthalimide；N-(4-amino-butyl)-phthalimide；δ-Aminobutylphthalimid；N-(4-Amino-butyl)-phthalimid；N-Phthaloyl-1,4-butandiamin；2-(4-aminobutyl)isoindole-1,3-dione
• CAS: 99008-43-2
• 化学式: C₁₂H₁₄N₂O₂
• mdl: MFCD09806296
• 分子量: 218.255
• InChiKey: GZCFMVCWRGPDLV-UHFFFAOYSA-N

物化性质

• 沸点：
  366.8±25.0 °C(Predicted)
• 密度：
  1.234±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  63.4
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-(4-aminobutyl)isoindoline-1,3-dione 在 碳酸氢钠 、 溶剂黄146 、 sodium chloride 作用下， 以 二氯甲烷 、 1,2-二氯乙烷 为溶剂， 反应 24.33h， 生成 1-N-{4-[(N,N-dimethyl)amino]benzyl}-1-N-[(tert-butyloxy)carbonyl]-4-phthalimidobutylamine
  参考文献：
  名称：

  Alkyl-Substituted Polyaminohydroxamic Acids:  A Novel Class of Targeted Histone Deacetylase Inhibitors

  摘要：

  The reversible acetylation of histones is critical for regulation of eukaryotic gene expression. The histone deacetylase inhibitors trichostatin (TSA, 1), MS-275 (2) and suberoylanilide, hydroxamic acid (SAHA, 3) arrest growth in transformed cells and in human tumor xenografts. However, 1-3 suffer from lack of specificity among the various HDAC isoforms, prompting us to design and synthesize polyaminohydroxamic acid (PAHA) derivatives 6-21. We felt that PAHAs would be selectively directed to chromatin and associated histones by the positively charged polyamine side chain. At 1 mu M, compounds 12, 15 and 20 inhibited HDAC by 74.86, 59.99 and 73.85%, respectively. Although 20 was a less potent HDAC inhibitor than 1, it was more potent than 2, more effective as an initiator of histone hyperacetylation, and significantly more effective than 2 at re-expressing p21(Waf1) in ML-1 leukemia cells. On the basis of these results, PAHAs 6-21 represent an important new chemical class of HDAC inhibitors.

  DOI：

  10.1021/jm0505009
• 作为产物：
  描述：

  N-(4-溴丁基)邻苯二甲酰亚胺 在 palladium 10% on activated carbon sodium azide 、 氢气 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 17.0h， 生成 2-(4-aminobutyl)isoindoline-1,3-dione
  参考文献：
  名称：

  WO2006/113606

  摘要：

  公开号：

文献信息

• Synthesis and properties of deoxyoligonucleotides containing putrescinylthymine (nucleosides and nucleotides. LXXVI).
  作者：TADAYUKI TAKEDA、KAZUYOSHI IKEDA、YOSHIHISA MIZUNO、TOHRU UEDA

  DOI：10.1248/cpb.35.3558

  日期：——

  Putrescinylthymidine was prepared by the reduction of the Schiff base formed from a 2'-deoxy-5-formyluridine derivative and N-phthaloylputrescine, followed by deprotection. The following deoxyoligonucleotides containing putrescinylthymine (TP) were synthesized; dodecathymidylic acids containing two to four TP residues, self-complementary decanucleotides (AAGAATTCTT) and dodecanucleotides (AGATAGCTATCT) in which T residues were partly replaced by TP, and related oligomers. Oligonucleotides containing TP were resistant to nuclease S1 digestion and were poor substrates to venom phosphodiesterase. The thermal stability (Tm) of the duplex structure of oligomers containing TP was not enhanced in spite of the expected electrostatic binding between the putrescinyl and phosphoryl residues, and was rather sequence-dependent.

  腐胺胸苷是通过从 2'-脱氧-5-甲酰尿苷衍生物和 N-邻苯二甲酰胺腐胺形成的希夫碱的还原反应制备的，随后进行去保护处理。合成了以下含有腐胺胸苷（TP）的脱氧寡核苷酸；含有两个到四个 TP 殘基的十二聚胸苷酸、自互补的十聚核苷酸（AAGAATTCTT）和十二聚核苷酸（AGATAGCTATCT），其中 T 残基部分被 TP 替代，以及相关的寡聚物。含有 TP 的寡核苷酸对核酸酶 S1 消化具抵抗性，并且是毒液磷酸二酯酶的劣质底物。尽管预计腐胺和磷酸残基之间存在静电结合，含有 TP 的寡聚物双链结构的热稳定性（Tm）并没有增强，而是相当依赖序列。
• [EN] NOVEL MODIFIED MACROCYCLIC COMPOUNDS<br/>[FR] NOUVEAUX COMPOSÉS MACROCYCLIQUES MODIFIÉS
  申请人：BAYER PHARMA AG

  公开号：WO2017060167A1

  公开（公告）日：2017-04-13

  The present invention relates to novel modified macrocyclic compounds of general formula (I) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (I).

  本发明涉及一种新型的改性大环化合物，其一般式为（I），如所述并定义，以及其制备方法，用于治疗和/或预防疾病，特别是高增殖性疾病和/或病毒引起的传染病和/或心血管疾病。该发明还涉及在制备所述一般式（I）化合物过程中有用的中间化合物。
• Modulators or Alpha7 Nicotinic Acetylcholine Receptors and Therapeutic Uses Thereof
  申请人：Gaviraghi Giovanni

  公开号：US20080275028A1

  公开（公告）日：2008-11-06

  The present invention relates to compounds with α7 nAChR agonistic activity, processes for their preparation, pharmaceutical compositions containing the same and the use thereof for the treatment of neurological, psychiatric, cognitive, immunological and inflammatory disorders.

  本发明涉及具有α7 nAChR激动活性的化合物，其制备方法，含有该化合物的制药组合物以及用于治疗神经、精神、认知、免疫和炎症性疾病的用途。
• MODIFIED BOVINE SOMATOTROPIN POLYPEPTIDES AND THEIR USES
  申请人：Ambrx, Inc.

  公开号：US20150152159A1

  公开（公告）日：2015-06-04

  Modified bovine somatotropin polypeptides and uses thereof are provided.

  提供了改良的牛生长激素多肽及其用途。
• Histone deacetylase inhibitors
  申请人：Casero Robert A.

  公开号：US20090182019A1

  公开（公告）日：2009-07-16

  The present invention provides novel HDAC inhibitors and methods of treating diseases using the same.

  本发明提供了新型HDAC抑制剂和使用其治疗疾病的方法。